Litcius/Paper detail

Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report

Jean‐Marie Michot, Laurence Albigès, Nathalie Chaput, Véronique Saada, Fanny Pommeret, Frank Griscelli, Corinne Balleyguier, Benjamin Besse, Aurélien Marabelle, Florence Netzer, Mansouria Merad, Caroline Robert, Fabrice Barlési, Bertrand Gachot, Annabelle Stoclin

2020Annals of Oncology343 citationsDOIOpen Access PDF

Topics & Concepts

MedicineCytokine stormImmunologyProinflammatory cytokineCytokineTumor necrosis factor alphaChemokineCoronavirusTocilizumabPathogenesisInflammationInternal medicineDiseaseCoronavirus disease 2019 (COVID-19)Rheumatoid arthritisInfectious disease (medical specialty)COVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 ResearchLong-Term Effects of COVID-19
Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report | Litcius